It is worth highlighting the great interest of the immune role in ER+ breast cancer, especially the antitumor immune response mediated by the programmed death 1/programmed death ligand 1 (PD1/PD-L1) and cytotoxic T lymphocyte antigen-4 inhibitors. This evidence concerns the gene CD274 and breast carcinoma.